Biohaven Stock Hits 52-Week Low, Cuts R&D Spending After FDA Rejection

benzinga.com/news/fda/25/11/48663214/biohaven-stock-hits-52-week-low-cuts-rd-spending-after-fda-rejection

Biohaven Ltd. (NYSE:BHVN) stock plummeted on Wednesday, reaching its 52-week low, according to data from Benzinga Pro.
BHVN is testing key support levels. View the charts here
The U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) to Biohaven's New Drug…

This story appeared on benzinga.com, 2025-11-05 17:53:02.
The Entire Business World on a Single Page. Free to Use →